The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | Ivosidenib with venetoclax in IDH1-mutated hematological malignancies
Farhad Ravandi, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the early results of a Phase Ib/II study (NCT03471260) evaluating the safety and response of ivosidenib and venetoclax with or without the addition of azacitidine in IDH1-mutated hematological malignancies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
